Welcome to our dedicated page for Jazz Pharmaceuticals news (Ticker: JAZZ), a resource for investors and traders seeking the latest updates and insights on Jazz Pharmaceuticals stock.
Jazz Pharmaceuticals plc reports developments across a global biopharma portfolio focused on rare diseases, including epilepsies, cancers and sleep disorders. Recurring updates cover commercial performance for Xywav, Epidiolex and oncology products, plus medical-conference data and real-world evidence for neuroscience and oncology programs.
Company news also includes regulatory and clinical progress for Ziihera (zanidatamab-hrii) in HER2-expressing tumors, including gastroesophageal adenocarcinoma and biliary tract cancer, along with research involving Zepzelca, Modeyso and other pipeline candidates. Updates frequently address financial results, guidance, investor conferences, collaborations and portfolio strategy.
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced that the FDA has granted Priority Review for zanidatamab, a HER2-targeted bispecific antibody, to treat HER2-positive metastatic biliary tract cancer (BTC). The target action date is set for November 29, 2024. If approved, zanidatamab will be the first HER2-targeted treatment for this condition. The submission is based on results from the Phase 2b HERIZON-BTC-01 trial, which showed a 41.3% confirmed objective response rate. Further data from this trial will be presented at the ASCO Annual Meeting 2024. Additionally, the Phase 3 HERIZON-BTC-302 trial is ongoing to evaluate zanidatamab in combination with standard-of-care therapy.
Jazz Pharmaceuticals announced a collaboration with Life Science Cares to enhance social impact via employee volunteerism in the U.S. This partnership aligns with Jazz's commitment to local communities where its employees reside. Life Science Cares leverages life sciences' financial and human capital to address poverty and inequality. The program will operate around Jazz's U.S. offices in Palo Alto, Philadelphia, and San Diego, encouraging employees to engage in meaningful volunteer activities. Jazz's Global Volunteer Day Policy allows employees to dedicate one paid workday annually to volunteer. Life Science Cares, active since 2016, has invested over $16 million and 55,000 volunteer hours to combat socio-economic disparities.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will participate in the BofA Securities 2024 Global Health Care Conference on May 15, 2024, in Las Vegas. The fireside chat will be held at 10:00 a.m. PT / 1:00 p.m. ET / 6:00 p.m. IST. An audio webcast will be available via the Investors section of the Jazz Pharmaceuticals website.
Jazz Pharmaceuticals plc is a global biopharma company focused on developing life-changing medicines for serious diseases. The company has a diverse portfolio of treatments for sleep disorders, epilepsy, and cancer. Jazz Pharmaceuticals is headquartered in Dublin, Ireland, with a commitment to serving patients worldwide.
Jazz Pharmaceuticals reported a 12% year-over-year revenue increase driven by key growth drivers Xywav, Epidiolex, and Rylaze. They submitted zanidatamab BLA for 2L BTC, expect to launch in 2025, and affirmed 2024 total revenue guidance at $4.0 to $4.2 billion. Various pipeline catalysts and near-term data releases are anticipated. Financials showed a decrease in Xyrem net product sales, an increase in Epidiolex/Epidyolex net product sales, and Rylaze/Enrylaze net product sales. The company provided extensive updates on their key commercial products, pipeline highlights, financial highlights, and 2024 financial guidance.
Jazz Pharmaceuticals is focusing on taking actions to positively impact the planet during Earth Month. They are reflecting on steps to become more conscious of their actions and promoting sustainable practices. For more information, read their Corporate Sustainability and Social Impact Report.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.